← 返回

慢性胰腺炎抗炎与抗纤维化治疗的研究进展

英文原题:The research progress of anti-inflammatory and anti-fibrosis treatment of chronic pancreatitis.

查看英文原题

The research progress of anti-inflammatory and anti-fibrosis treatment of chronic pancreatitis.

PubMed 2022/11/24(内容时间) Front Oncol Q2 · IF 3.4(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

慢性胰腺炎(CP)是一种由多种因素引起的胰腺慢性进行性炎症性疾病,并伴有胰腺内、外分泌功能不可逆损害。病理表现包括胰腺腺泡萎缩、组织纤维化或钙化、局灶性水肿、炎症和坏死。临床表现包括反复或持续腹痛、腹泻、消瘦和糖尿病。此外,持续炎症和纤维化使CP容易进展为胰腺癌(PC)。该病病程长,临床预后较差。目前CP的临床治疗仍以对症处理为主,缺乏有效的病因治疗。值得关注的是,实验研究显示,多种活性物质在慢性胰腺炎病因治疗方面具有潜力。本文综述CP发病机制以及抗炎和抗纤维化治疗的研究进展,为后续临床研究和制定有效治疗方案提供新思路,并有助于预防CP进展为胰腺癌,尽可能降低PC发病率。

展开英文摘要原文

Chronic pancreatitis (CP) is a chronic progressive inflammatory disease of the pancreas, caused by multiple factors and accompanied by irreversible impairment of pancreatic internal and external secretory functions. Pathologically, atrophy of the pancreatic acini, tissue fibrosis or calcification, focal edema, inflammation, and necrosis are observed. Clinical manifestations include recurrent or persistent abdominal pain, diarrhea, emaciation, and diabetes.

In addition, CP is prone to develop into pancreatic cancer(PC) due to persistent inflammation and fibrosis. The disease course is prolonged and the clinical prognosis is poor. Currently, clinical treatment of CP is still based on symptomatic treatment and there is a lack of effective etiological treatment. Encouragingly, experiments have shown that a variety of active substances have great potential in the etiological treatment of chronic pancreatitis.

In this paper, we will review the pathogenesis of CP, as well as the research progress on anti-inflammatory and anti-fibrotic therapies, which will provide new ideas for the development of subsequent clinical studies and formulation of effective treatment programs, and help prevent CP from developing into pancreatic cancer and reduce the prevalence of PC as much as possible.

论文信息

作者
Li BQ、Liu XY、Mao T、Zheng TH、Zhang P、Zhang Q、Zhang Y、Li XY
单位
Department of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao, China.China
文献类型
综述
期刊
Frontiers in oncology2022
原文标识
PubMed 36505827 · DOI 10.3389/fonc.2022.1050274